GlassScriptPhysician profile
Ramez R Sunna
NPI 1518245216
$3,314.75
in general payments reported to CMS, 2019-2025
21 companies · $604 in 2025
The $604 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $80.35 · 2021: $12.06 · 2022: $40.13 · 2023: $132 · 2024: $2,197 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,751 · Food and Beverage: $1,178 · Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,751.41 |
| Food and Beverage | $1,177.75 |
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,751.41 | 2024 | |
| Vifor Pharma, INC. | $216.87 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $155.87 | 2019-2025 | Jynarque |
| Medtronic, INC. | $133.70 | 2025 | Symplicity G3 |
| Fresenius USA Marketing, INC. | $119.78 | 2019-2024 | Velphoro, Korsuva, Crit-Line |
| Vantive US Healthcare LLC | $117.17 | 2025 | Renal - Pd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.80 | 2023-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $104.92 | 2024-2025 | Tarpeyo |
| Novo Nordisk INC | $91.07 | 2024-2025 | Ozempic |
| Amgen INC. | $90.13 | 2019-2025 | Tavneos, Krystexxa |
| Novartis Pharmaceuticals Corporation | $79.55 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $77.12 | 2023-2025 | Farxiga, Lokelma |
| Akebia Therapeutics INC | $57.36 | 2019 | |
| Travere Therapeutics, INC. | $53.02 | 2023-2025 | |
| Glaxosmithkline, LLC. | $40.77 | 2024-2025 | Benlysta |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cormedix INC. | $28.76 | 2024 | Defencath |
| Alnylam Pharmaceuticals INC. | $23.04 | 2025 | Givlaari |
| Scpharmaceuticals INC. | $19.11 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.60 | 2024 | |
| Nxstage Medical, INC. | $16.68 | 2019 | |
| Horizon Therapeutics Plc | $14.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramez Sunna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.